From Reset to Readiness: Navigating the Life Science Real Estate Market in 2026

Life science real estate markets are at a reset that’s a historical norm for the sector. The pattern of expansion, overheated peak and uneven correction is familiar both in the Research Triangle and across North America. How do we assess where the market actually stands, the structural forces shaping demand, and what real estate and site selection decision-makers should consider in the near and longer term?

The Oversupply Overhang: What the Numbers Say
The headline figures remain sobering for anyone with exposure to the top-tier life science markets. Leasable life science inventory across the United States stands at roughly 200 million square feet, with national vacancy running at approximately 23.5 percent. But that aggregate number masks a more acute problem in the markets that matter most. Boston, the San Francisco Bay Area and San Diego collectively account for around 130 million square feet of that inventory — and vacancy in those three markets has climbed above 30 percent, a direct consequence of the speculative development boom that peaked around 2021–2022.

Click here to read the original article from Area Development.